Pfizer Inc ($PFE) announced an update on their ongoing clinical study. Pfizer has completed a Phase 1 trial titled “A Phase 1, Randomized, ...

Please provide your email address to receive an email when new articles are posted on . Acne vulgaris may be driven by underlying systemic, immune-inflammatory pathways. Addressing those underlying ...

Please provide your email address to receive an email when new articles are posted on . Denifanstat, a fatty acid synthase inhibitor, was effective in the treatment of moderate to severe acne vulgaris ...

Credit: Getty Images. The Food and Drug Administration (FDA) has approved Amzeeq (minocycline; Foamix) topical foam 4% for the treatment of inflammatory lesions of non-nodular moderate to severe acne ...

Acne vulgaris is a multifactorial skin disorder marked by inflammatory and non-inflammatory lesions that can cause significant physical and psychological distress. Traditional treatment options, ...

Acne vulgaris is one of the commonest skin disorders, which dermatologists treat and it mainly affects adolescents, though it may appear at any age. Acne by definition is multifactorial chronic ...

Choosing the best treatments for acne The disfiguring lesions of acne vulgaris can have a severe psychological impact. Fortunately, clinicians now have a broad range of therapeutic options. Acne ...

LAVAL, QC / ACCESSWIRE / April 11, 2024 / Bausch Health, Canada Inc., part of Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), today announced that its topical prescription treatment for acne ...

The MarketWatch News Department was not involved in the creation of this content. The dynamics of the acne vulgaris market are anticipated to change in the coming years owing to the increase in the ...

Active ingredients: Clindamycin (as phosphate) 1.2%, benzoyl peroxide 2.5%; gel. Indication: Topical treatment of acne vulgaris. Pharmacology: Acanya gel combines the lincosamide antibiotic, ...